Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.

摘要: Lowering of low-density lipoprotein (LDL) cholesterol is a fundamental step in the comprehensive management patients at high risk for cardiovascular events. The combination statin with ezetimibe usually provides additional LDL lowering compared to monotherapy. This open-label observational study evaluated impact 26-week treatment program uptitration dosages and incorporation 10 mg therapy 2,577 men women (median age 64 years) hypercholesterolemia an level >2.5 mmol/L (97 mg/dl). Attainment target 2.5 mg/dl) increased consecutive visits (63%, 67%, 71% second, third, final visits, respectively). Current guideline-recommended value